Vanderbilt researchers led a clinical trial combining atezolizumab (Tecentriq), an immunotherapy, in combination with chemotherapy in patients with metastatic triple-negative breast cancer to both evaluate the efficacy of the treatment combination and to understand biomarkers of response to immunotherapy.
A decision-making aid to help women at high risk of breast cancer decide whether to add MRIs to their screening regimen has proved popular with both patients and doctors alike in early testing.
A team of Wistar researchers led by Hildegund C.J. Ertl—a professor in The Wistar Institute’s Vaccine & Immunotherapy Center—has demonstrated that the common cholesterol drug fenofibrate can boost T cells’ ability to destroy human tumors. The study was published in Molecular Therapy Oncolytics.
Cedars-Sinai investigators have discovered how the liver defends itself against cancer. Their study, published in the peer-reviewed Journal of Hepatology, suggests targets for therapies to protect the liver both from cancers that originate there and cancers that spread to the liver from other parts of the body.
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups—including white or Latino men—despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.
A report suggests that Lung-MAP, which for almost a decade has undergirded the first NCI-sponsored precision medicine clinical trial in lung cancer, can serve as a model for future clinical research that is more rapid, innovative, and inclusive.
A study of the relationship between the enzyme DDX5, liver cancer and sorafenib, published in the Nature journal Cell Death & Disease points to the potential for a more effective therapy that combines existing anti-cancer drugs with treatments that spur production of this enzyme.
Researchers have developed a method to predict early on which patients with breast cancer are most likely to stop taking potentially life-saving aromatase inhibitor drugs.
FDA has received reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies.
A planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma produced positive headline results.
